Top

BMC Psychiatry

Published in:

Open Access 01-12-2021 | Schizophrenia | Research

The screen for cognitive impairment in psychiatry (SCIP) as a routinely applied screening tool: pathology of acute psychiatric inpatients and cluster analysis

Authors: Petra Schmid, Agata Czekaj, Jürgen Frick, Tilman Steinert, Scot E. Purdon, Carmen Uhlmann

Published in: BMC Psychiatry | Issue 1/2021

Abstract

Background

Cognitive dysfunction has been reported in acute psychiatric patients for a long time. The detection of cognitive deficits is crucial both for clinical treatment and for predicting the psychosocial functional level in the further course of the disease. The SCIP is a well-evaluated screening instrument for the examination of cognitive performance in psychiatric patients. We recently integrated the SCIP into our routine admission and discharge assessments on two inpatient wards, and we examined the cognitive profiles of patients with psychotic and affective disorders over the course of their admission.

Methods

Shortly after admission, and prior to discharge, patients were routinely referred for examination with the SCIP. A total of 529 assessments were completed on admission, and 227 returned for SCIP at the time of discharge. After standardization of the test results against a normative sample, we examined the normalized test values in terms of percentages of pathological cognitive performance based on the total SCIP score, and each of the SCIP subscale scores. We conducted cluster analysis to identify cognitive subgroups within the clinical sample.

Results

More than 70% of the SCIP results on admission were pathological. At discharge, improvements were observed, especially on tests with attention and speed components. Cluster analysis identified two groups. The cluster with chronic patients showed poorer results at admission, but greater improvement and reached the level of the others at discharge.

Conclusions

The SCIP appears to have value in routine diagnostic assessments, and in the quantification of improvements in cognitive performance during an inpatient stay. The greatest benefit was observed in chronically ill patients with many previous stays.

Trial registration

DRKS00019825 (retrospectively registered on 03.12.2019).

Kraepelin E (1899). Psychiatrie. Ein Lehrbuch für Studierende und Aerzte. 6. Aufl., Leipzig.

Murri MB, Folesani F, Costa S, Biancosino B, Colla C, Zerbinati L, Caruso R, Nanni MG, Purdon SE, Grassi L. Screening for cognitive impairment in non-affective psychoses: A comparison between the SCIP and the MoCA. Schizophrenia Res 2020; 218: 188–194. doi.org/https://doi.org/10.1016/j.schres.2020.01.005

Mesholam-Gately RI, Giuliano AJ, Go KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology 2009; 23: 315–336. doi.org/https://doi.org/10.1037/a0014708

Zanelli J, Mollon J, Sandin S, Morgan C, Dazzan P, Pilecka I, et al. Cognitive change in schizophrenia and other psychoses in the decade following the first episode. Am J Psychiatry. 2019:appiajp201918091088. https://doi.org/10.1176/appi.ajp.2019.18091088.

Dickinson T, Becerra R, Coombes J. Executive functioning deficits among adults with bipolar disorder (types I and II): a systematic review and meta-analysis. J Affect Disord. 2017;218:407–27. https://doi.org/10.1016/j.jad.2017.04.010.CrossRefPubMed

Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):2029–40. https://doi.org/10.1017/S0033291713002535.CrossRefPubMed

Ahern E, Semkovska M. Cognitive functioning in the first-episode of major depressive disorder: a systematic review and meta-analysis. Neuropsychology. 2017;31(1):52–72. https://doi.org/10.1037/neu0000319.CrossRefPubMed

Gómez-Benito J, Guilera G, Pino Ó, Rojo E, Tabarés-Seisdedos R, Safont G, et al. The screen for cognitive impairment in psychiatry: diagnostic-specific standardization in psychiatric ill patients. BMC Psychiatry. 2013;13(1):127. https://doi.org/10.1186/1471-244X-13-127.CrossRefPubMedPubMedCentral

Hill SK, Reilly JL, Harris MS, Rosen C, Marvin RW, Deleon O, et al. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia. Schizophr Res. 2009;113(2–3):167–75. https://doi.org/10.1016/j.schres.2009.04.020.CrossRefPubMedPubMedCentral

10.

Neu P, Gooren T, Niebuhr U, Schlattmann P. Cognitive impairment in schizophrenia and depression: a comparison of stability and course. Appl Neuropsychol Adult. 2019;26(3):215–28. https://doi.org/10.1080/23279095.2017.1392962.CrossRefPubMed

11.

Sachs G, Maihofer E, Erfurth A. Are deficits in social cognition differentiating between schizophrenia and affective disorders. Eur Psychiatry 2017; 41 Sup: S44–S45. DOI: doi.org/https://doi.org/10.1016/j.eurpsy.2017.01.196

12.

Bonner-Jackson A, Grossman LS, Harrow M, Rosen C. Neurocognition in schizophrenia: a 20-yearmulti-follow-upofthecourseofprocessing speed and stored knowledge. Compr Psychiatry 2010; doi.org/https://doi.org/10.1007/s00406-019-01030-z, 2020.

13.

Wu C, Dagg P, Molgat C. Measuring stability of cognitive impairment in inpatients with schizophrenia with alternate forms of the Montreal cognitive assessment during acute hospitalization. Psychiatry Res. 2017;258:299–304. https://doi.org/10.1016/j.psychres.2017.08.065.CrossRefPubMed

14.

Krug A, Stein F, Kircher T. Kognitive Störungen bei Schizophrenie. Cognitive disorders in schizophrenia. Der Nervenarzt. 2020;91(1):2–9. https://doi.org/10.1007/s00115-019-00809-8.

15.

Christensen TØ. The influence of neurocognitive dysfunctions on work capacity in schizophrenia patients: a systematic review of the literature. Int J Psychiatry Clin Pract 2007; 11: 89–101. doi.org/https://doi.org/10.1080/13651500600969061

16.

Malla AK, Norman RMG, Manchanda R, Townsend L. Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis. Psychol Med 2002; 32: 1109–1119. doi.org/https://doi.org/10.1017/S0033291702006050

17.

Tourjman SV, Juster R-P, Purdon S, Stip E, Kouassi E, Potvin S. The screen for cognitive impairment in psychiatry (SCIP) is associated with disease severity and cognitive complaints in major depression. Int J Psychiatry Clin Pract. 2018;23(1):49–56. https://doi.org/10.1080/13651501.2018.1450512.CrossRefPubMed

18.

Caletti E, Paoli RA, Fiorentini A, Cigliobianco M, Zugno E, Serati M, et al. Neuropsychology, social cognition and global functioning among bipolar, schizophrenic patients and healthy controls: preliminary data. Front Hum Neurosci. 2013;7:661. https://doi.org/10.3389/fnhum.2013.00661.CrossRefPubMedPubMedCentral

19.

Knight MJ, Air T, Baune BT. The role of cognitive impairment in psychosocial functioning in remitted depression. J Affect Disord. 2018;235:129–34. https://doi.org/10.1016/j.jad.2018.04.051.CrossRefPubMed

20.

Medalia A, Saperstein AM. Does cognitive remediation for schizophrenia improve functional outcomes? Curr Opin Psychiatry. 2013;26(2):151–7. https://doi.org/10.1097/YCO.0b013e32835dcbd4.CrossRefPubMed

21.

Purdon SE. The screen for cognitive impairment in psychiatry (SCIP): instructions and three alternate forms. Edmonton, Alberta: PNL Inc; 2005.

22.

Keefe RSA, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The brief assessement of cognition in schizophrenia: reliability, sensitivity, and comparison with standard neurocognitive battery. Schizophr Res 2004; 68: 283-297.doi.org/https://doi.org/10.1016/j.schres.2003.09.011

23.

Nasreddine Z. The Montreal cognitive assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005; 695–699. doi.org/https://doi.org/10.1111/j.1532-5415.2005.53221.x

24.

Cuesta MJ, Pino O, Guilera G, Rojo JE, Gómez-Benito J, Purdon SE, et al. Brief cognitive assessment instruments in schizophrenia and bipolar patients, and healthy control subjects: a comparison study between the brief cognitive assessment tool schizophrenia (B-CATS) and the screen for cognitive impairment in psychiatry (SCIP). Schizophr Res. 2011;130(1-3):137–42. https://doi.org/10.1016/j.schres.2011.05.020.CrossRefPubMed

25.

Guilera G, Pino O, Gómez-Benito J. Clinical usefulness of the screen for cognitive impairment in psychiatry (SCIP-S) scale in patients with type I bipolar disorder. Health Qual Life Outcomes. 2009;7(1):28. https://doi.org/10.1186/1477-7525-7-28.CrossRefPubMedPubMedCentral

26.

Pino O, Guilera G, Rojo JE, Gómez-Benito J. et al. Spanish version of the Screen for Cognitive Impairment in Psychiatry (SCIP-S): psychometric properties of a brief scale for cognitive evaluation in schizophrenia. Schizophr Res. 2008; 99(1–3):b139–b148. doi.org/https://doi.org/10.1016/j.schres.2007.09.012

27.

Rojo E, Pino O, Guilera G, Gómez-Benito J, Purdon SE, Crespo-Facorro B, et al. Neurocognitive diagnosis and cut-off scores of the screen for cognitive impairment in psychiatry (SCIP-S). Schizophr Res. 2010;116(2–3):243–51. https://doi.org/10.1016/j.schres.2009.08.005.CrossRefPubMed

28.

Ott CV, Bjertruo AJ, Jensen JH, Ullum H et al. Screening for cognitive dysfunction in unipolar depression: validation and evaluation of objective and subjective tools. J Affect Disord 2016; 190: 607–615. doi.org/https://doi.org/10.1016/j.jad.2015.10.059

29.

Tourjman SV, Beauchamp MH, Djouini A, Neugot-Cerioli M, Gagner C, Baruch P, et al. French validation of the screen for cognitive impairment in psychiatry (SCIP-F). Open J Psychiatry. 2016;6(01):107–18. https://doi.org/10.4236/ojpsych.2016.61013.CrossRef

30.

Czekaj A, Uhlmann C, Flammer E, Frick J. et al. Klinische Praktikabilität der "Erfassung kognitiver Beeinträchtigung" bei Patienten der Allgemeinpsychiatrie (Screen for Cognitive Impairment in Psychiatry/SCIP). Posterpräsentation, DGPPN, Berlin, 21.-24.11.2012.

31.

Oswald WD, Roth R. Zahlen-Verbindungs-Test (ZVT). Göttingen: Hogrefe; 1987.

32.

Czekaj A, Steinert T, Uhlmann C. Klinische Routinediagnostik kognitiver Beeinträchtigungen. Psychiatr Prax. 2014;41(3):166–7. https://doi.org/10.1055/s-0033-1336945.CrossRefPubMed

33.

Jaeger S, Flammer E, Steinert T. Basisdokumentation in der klinischen Praxis: Wie zuverlässig sind BADO-Daten? Psychiatr Prax. 2011;38(05):244–9. https://doi.org/10.1055/s-0030-1266084.CrossRefPubMed

34.

Field A. Discovering Statistics using SPSS. London: Sage Publications Ltd; 2005.

35.

Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. 1988. https://doi.org/https://doi.org/10.1234/12345678.

36.

Purdon SE, Jones BD, Stip E, Labelle A, Addington D, David SR, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian collaborative group for research in schizophrenia. Arch Gen Psychiatry. 2000;57(3):249–58. https://doi.org/10.1001/archpsyc.57.3.249.CrossRefPubMed

37.

Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005;8(3):457–72. https://doi.org/10.1017/S146114570500516X.CrossRefPubMed

38.

Rodriguez M, Zaytseva Y, Cvrčková A. Cognitive profiles and functional connectivity in first-episode schizophrenia Spectrum disorders - linking behavioral and neuronal data. Front Psychol. 2019;10:689. https://doi.org/10.3389/fpsyg.2019.00689.CrossRefPubMedPubMedCentral

39.

Moritz S, Klein JP, Desler T, Lill H, Gallinat J, Schneider BC. Neurocognitive deficits in schizophrenia. Are we making mountains out of molehills? Psychol Med. 2017;47(15):2602–12. https://doi.org/10.1017/S0033291717000939.CrossRefPubMed

Title: The screen for cognitive impairment in psychiatry (SCIP) as a routinely applied screening tool: pathology of acute psychiatric inpatients and cluster analysis
Authors: Petra Schmid
Agata Czekaj
Jürgen Frick
Tilman Steinert
Scot E. Purdon
Carmen Uhlmann
Publication date: 01-12-2021
Publisher: BioMed Central
Keyword: Schizophrenia
Published in: BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI: https://doi.org/10.1186/s12888-021-03508-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The screen for cognitive impairment in psychiatry (SCIP) as a routinely applied screening tool: pathology of acute psychiatric inpatients and cluster analysis

Abstract

Background

Methods

Results

Conclusions

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2021

Suicide attempt risks among hotline callers with and without the coronavirus disease 2019 related psychological distress: a case-control study

Low intensity technology-delivered cognitive behavioral therapy for obsessive-compulsive disorder: a meta-analysis

The experiences and strategies of parents’ of adults with anorexia nervosa or bulimia nervosa: a qualitative study

Depression, post-traumatic stress, anxiety, and fear of COVID-19 in the general population and health-care workers: prevalence, relationship, and explicative model in Peru

Association between sleep quality and depression among institutionalized and community older people - Brazilian Western Amazonia

Benign ethnic neutropenia: an analysis of prevalence, timing and identification accuracy in two large inner-city NHS hospitals